Full Breakdown
Trump Administration Ends Federal Funding for Fentanyl Test Strips
5/2/2026, 1:57:15 AM
Core Policy Shift
The Substance Abuse and Mental Health Services Administration (SAMHSA) issued a “Dear Colleague” letter stating that federal grant money may no longer be used to purchase or distribute fentanyl test strips intended for people who use drugs. The guidance cites an executive order signed by President Donald Trump in July 2025 that bars funding for programs “that only facilitate illegal drug use.” Funding may still support test strips used by public-health officials, law-enforcement personnel, or medical workers.
Policy Background and Harm-Reduction History
SAMHSA began supporting harm-reduction tools, including test strips, in 2021 under the Biden administration. A July 2025 SAMHSA notice listed the strips as eligible for grant support, and the 2018 SUPPORT Act, reauthorized in 2025, protected their use. The current reversal aligns with the Trump administration’s broader shift toward an abstinence-first model and away from interventions it describes as “ideological concepts” that “facilitate illegal drug use.”
Key Stakeholders and Funding Impacts
- SAMHSA / HHS – Issued the funding guidance and emphasized continued support for naloxone, sharps-disposal kits, and infectious-disease testing.
- Drug Policy Alliance – Maritza Perez Medina, director of federal policy, called the change “astonishing” and warned it removes “low-barrier” tools that save lives.
- Kentucky Harm Reduction Coalition – Executive director Shreeta Waldon reported a lost $400,000 grant after distributing 48,465 test strips in the first quarter of fiscal 2026.
- Fyrebird Recovery (South Carolina) – Founder A’zhane Powell noted the loss of a $4,000 grant, stressing the strain on an organization already operating on tight margins.
- Center for Prevention Services (North Carolina) – Lauren Kestner warned that the policy could limit access to pass-through block-grant funding for a range of services.
Data on Overdose Trends and Test-Strip Use
- Overdose deaths fell from 111,000 in 2023 to roughly 68,000 for the 12-month period ending November 2025 (CDC).
- Test strips cost about $1 each and can detect fentanyl, xylazine, and medetomidine.
- Kentucky Harm Reduction Coalition’s 48,465 distributed strips represent a month-long supply before the grant loss creates a “full-blown crisis.”
Official Statements from Federal Agencies
SAMHSA’s letter clarified that the new rule “prioritizes life-saving interventions such as naloxone” while restricting funding for strips used by drug users. A Health and Human Services spokesperson described the guidance as aligning federal money with “common-sense public health strategies that focus on prevention, treatment, and long-term recovery.” The administration reiterated support for overdose-reversal medication naloxone and other proven interventions.
Criticism from Harm-Reduction Advocates
Advocates argue the policy contradicts evidence-based practice. Waldon said, “It doesn’t make sense that one day something is an evidence-based protocol, and you decide, because of political climate, it is no longer evidence-based.” Powell questioned, “How far will it go until we’re back to square one again?” Medina warned that “gutting all the things that work” could leave people seeking help with “no doors open.”
Conflicting Interpretations and Gaps
SAMHSA permits test-strip funding for professional settings, yet harm-reduction groups contend that the restriction effectively eliminates access for the intended users. The SUPPORT Act’s protection of test-strip use appears at odds with the new guidance, creating legal ambiguity. State-level legalization of strips (e.g., Nevada, California, North Carolina) further highlights the mismatch between federal funding and local policy.
Verbatim Quotes
- “There has been a lot of confusion about where this came from.” — Maritza Perez Medina, Drug Policy Alliance
- “It doesn't make sense that one day something is an evidence-based protocol, and you decide, because of political climate, it is no longer evidence-based,” — Shreeta Waldon, Kentucky Harm Reduction Coalition
- “How far will it go until we're back to square one again?” — A’zhane Powell, Fyrebird Recovery
- “To finally bring an end to this crisis and achieve the Great American Recovery, it is essential that the use of federal funding is aligned to common-sense public health strategies that focus on prevention, treatment, and long-term recovery.” — Statement from the Trump administration
- “Our fear is that if we are gutting all the things that work, that when people seek help, they won't find any doors open," Medina said.” — Maritza Perez Medina, Drug Policy Alliance
Outlook and Potential State Responses
Advocates urge states to allocate opioid-settlement funds to sustain test-strip distribution and to lobby for legislative clarification of the SUPPORT Act’s protections. Continued federal emphasis on naloxone and other medical interventions suggests a partial mitigation strategy, but the loss of dedicated funding for user-focused test strips may reshape harm-reduction capacity at the community level.
